This drug has proved to improve overall survival in adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation [31] and could be useful for the treatment of specific T-ALL subsets [23]. This evidence concerns the gene BRAF and acute lymphoblastic leukemia.